Search the Newsreel

Evolus Inc (EOLS) Dividends & Stock Splits: Historical Payouts and Event Timeline

The article provides information regarding Evolus Inc (EOLS) stock, focusing on its dividend history. It states that Evolus Inc has not distributed any dividends over the past five years. The page displays current stock metrics such as its closing price, market capitalization, and P/E …

Evolus, Inc. Common Stock Revenue Breakdown – NASDAQ:EOLS

Evolus, Inc. (NASDAQ: EOLS) generated $297.18 million USD in revenue last year, primarily from its Medical Aesthetics segment. All of this revenue came from the United States, which contributed $297.18 million USD last year, an increase from $253.16 million USD the previous year. This …

Evolus Inc (EOLS) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Evolus Inc (EOLS) from TradingKey. The company currently has a valuation score of 9.32, which ranks it 30th out of 155 in the Pharmaceuticals industry. While its current P/E ratio is -9.25, the article notes that key …

Press Release: Evolus to Report Second Quarter Financial Results on August 5, 2026

Evolus, Inc. announced it will release its second quarter financial results on August 5, 2026. The announcement will be followed by a conference call and webcast for investors and analysts to discuss the results and provide a business update.

Evolus Sets Aug. 5 Webcast to Discuss Second-Quarter Results

(EOLS) and the Role of Price-Sensitive Allocations

This article provides an AI-generated analysis of Evolus Inc. (NASDAQ: EOLS) revealing weak sentiment across all time horizons, suggesting a short bias. It outlines three distinct trading strategies (Position Trading, Momentum Breakout, and Risk Hedging) with specific entry, target, and stop-loss levels. The analysis …

Evolus, Inc. (EVL) Q3 2025 Earnings Report - Results, Call & Slides

Evolus, Inc. (EVL) reported its Q3 2025 earnings, surpassing analyst expectations with an actual EPS of -€0.12 against a consensus of -€0.14, and actual revenue of €60.28M against an expected €58.90M. The company experienced a 12.90% year-over-year revenue growth. The next earnings report for …

Analysts Conflicted on These Healthcare Names: Irhythm Technologies (IRTC), Penumbra (PEN) and Evolus (EOLS)

This article highlights recent analyst ratings for several healthcare companies. Irhythm Technologies (IRTC) received a "Strong Buy" consensus with a significant upside, while Penumbra (PEN) garnered a "Hold" consensus. Evolus (EOLS) also received a "Strong Buy" consensus rating with a high potential upside.